EGFR and head and neck cancer: Epidermal growth factor receptor (EGFr) antibody or inhibitor could also increase the efficacy of the regimen: first by improving the therapeutic effect of irinotecan via EGFr antibodies as demonstrated in vitro (Prewett et al, 2002), second by the specific approach as demonstrated in head and neck cancer, by using radiation therapy and EGF receptor antibodies (Bonner et al, 2006; Pfister et al, 2006).